BR112018012106A2 - forma cristalina de inibidor de btk quinase e método de preparação da mesma - Google Patents
forma cristalina de inibidor de btk quinase e método de preparação da mesmaInfo
- Publication number
- BR112018012106A2 BR112018012106A2 BR112018012106-1A BR112018012106A BR112018012106A2 BR 112018012106 A2 BR112018012106 A2 BR 112018012106A2 BR 112018012106 A BR112018012106 A BR 112018012106A BR 112018012106 A2 BR112018012106 A2 BR 112018012106A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- kinase inhibitor
- crystalline form
- btk kinase
- crystal
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 3- (4-amino-3- (4- (2,6-difluorophenoxy) phenyl) -7-hydroxy-1h- pyrrolo [2,3-d] pyridaz-1-yl) pyrrolidin-1-yl Chemical group 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção refere-se a uma forma cristalina de um inibidor da btk quinase e ao método de preparação da mesma. em particular, a presente invenção refere-se a um cristal tipo i de (r)-1-(3-(4-amino-3-(4-(2,6-difluorofenóxi)fenil)-7-hidróxi-1h-pirrolo[2,3-d]piridaz-1-il)pirrolidin-1-il)butil-2-alquina-1-cetona (o composto na fórmula (i)) e ao método de preparação do mesmo. o cristal tipo i do composto da fórmula (i) obtido pela presente invenção tem uma boa estabilidade cristalina e estabilidade química e o solvente de cristal usado tem uma toxicidade e resíduo baixos tornando desta maneira o mesmo mais adequado para o uso em tratamento clínico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610006080 | 2016-01-05 | ||
| CN201610006080.0 | 2016-01-05 | ||
| PCT/CN2016/111051 WO2017118277A1 (zh) | 2016-01-05 | 2016-12-20 | 一种btk激酶抑制剂的结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018012106A2 true BR112018012106A2 (pt) | 2018-12-04 |
| BR112018012106B1 BR112018012106B1 (pt) | 2023-12-12 |
Family
ID=59273271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018012106-1A BR112018012106B1 (pt) | 2016-01-05 | 2016-12-20 | Forma cristalina i de (r)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)-3-(4- (2,6- difluorofenoxi)fenil)-1h-pirrolo[2,3-d]piridazin-7(6h)-ona, método de preparar a forma cristalina i, composição farmacêutica e uso da forma cristalina i |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10626116B2 (pt) |
| EP (1) | EP3372607B1 (pt) |
| JP (1) | JP6913274B2 (pt) |
| KR (1) | KR102688907B1 (pt) |
| CN (1) | CN107406453B (pt) |
| AU (1) | AU2016384921C1 (pt) |
| BR (1) | BR112018012106B1 (pt) |
| CA (1) | CA3009256C (pt) |
| ES (1) | ES2875384T3 (pt) |
| HK (1) | HK1243419B (pt) |
| MX (1) | MX2018008131A (pt) |
| PL (1) | PL3372607T3 (pt) |
| RU (1) | RU2728827C2 (pt) |
| TW (1) | TWI726030B (pt) |
| WO (1) | WO2017118277A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017137532A1 (en) | 2016-02-12 | 2017-08-17 | Akzo Nobel Chemicals International B.V. | Process to prepare higher ethylene amines and ethylene amine derivatives |
| WO2019196915A1 (zh) * | 2018-04-13 | 2019-10-17 | 江苏恒瑞医药股份有限公司 | 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体 |
| US20210308140A1 (en) | 2018-07-25 | 2021-10-07 | Novartis Ag | Nlrp3 inflammasome inhibitors |
| US20220362357A1 (en) | 2018-08-31 | 2022-11-17 | Stichting Radboud Universitair Medisch Centrum | Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof |
| CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US20220233449A1 (en) * | 2019-05-31 | 2022-07-28 | Jiangsu Hengrui Medicine Co., Ltd. | Solid dispersion and preparation method therefor |
| CN110372562B (zh) * | 2019-07-09 | 2021-04-06 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的晶型及其制备方法 |
| CN112745255A (zh) * | 2019-10-30 | 2021-05-04 | 江苏恒瑞医药股份有限公司 | 一种btk激酶抑制剂的制备方法 |
| CN115701997B (zh) * | 2020-08-10 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| AR123241A1 (es) | 2020-08-14 | 2022-11-09 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| WO2022261138A1 (en) | 2021-06-08 | 2022-12-15 | Tg Therapeutics, Inc. | Disrupted ikaros signaling as biomarker for btk inhibition |
| CN114751850B (zh) * | 2022-06-06 | 2023-08-25 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂关键中间体的制备方法 |
| CN114989062A (zh) * | 2022-07-04 | 2022-09-02 | 上海再启生物技术有限公司 | 一种btk激酶抑制剂中间体的晶型及其制备方法 |
| US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| EP2954900A1 (en) | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| WO2011060440A2 (en) | 2009-11-16 | 2011-05-19 | The Regents Of The University Of California | Kinase inhibitors |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| KR102073797B1 (ko) * | 2014-07-07 | 2020-02-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 단백질 키나제 저해제로서의 아미노피리다지논 화합물 |
| JP7125952B2 (ja) * | 2017-05-18 | 2022-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用 |
-
2016
- 2016-12-20 MX MX2018008131A patent/MX2018008131A/es active IP Right Grant
- 2016-12-20 CN CN201680013136.3A patent/CN107406453B/zh active Active
- 2016-12-20 CA CA3009256A patent/CA3009256C/en active Active
- 2016-12-20 RU RU2018125277A patent/RU2728827C2/ru active
- 2016-12-20 JP JP2018530708A patent/JP6913274B2/ja active Active
- 2016-12-20 BR BR112018012106-1A patent/BR112018012106B1/pt active IP Right Grant
- 2016-12-20 US US16/067,229 patent/US10626116B2/en active Active
- 2016-12-20 WO PCT/CN2016/111051 patent/WO2017118277A1/zh active Application Filing
- 2016-12-20 PL PL16883403T patent/PL3372607T3/pl unknown
- 2016-12-20 EP EP16883403.4A patent/EP3372607B1/en active Active
- 2016-12-20 ES ES16883403T patent/ES2875384T3/es active Active
- 2016-12-20 KR KR1020187021656A patent/KR102688907B1/ko active IP Right Grant
- 2016-12-20 AU AU2016384921A patent/AU2016384921C1/en active Active
- 2016-12-29 TW TW105143911A patent/TWI726030B/zh active
-
2018
- 2018-03-02 HK HK18103056.5A patent/HK1243419B/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018008131A (es) | 2018-09-03 |
| CN107406453B (zh) | 2018-12-28 |
| EP3372607A1 (en) | 2018-09-12 |
| TWI726030B (zh) | 2021-05-01 |
| HK1243419B (zh) | 2019-11-22 |
| EP3372607A4 (en) | 2018-10-03 |
| KR20180099787A (ko) | 2018-09-05 |
| TW201725207A (zh) | 2017-07-16 |
| PL3372607T3 (pl) | 2021-09-20 |
| AU2016384921B2 (en) | 2020-10-15 |
| RU2018125277A3 (pt) | 2020-02-28 |
| WO2017118277A1 (zh) | 2017-07-13 |
| CN107406453A (zh) | 2017-11-28 |
| US20190010161A1 (en) | 2019-01-10 |
| JP2019500357A (ja) | 2019-01-10 |
| RU2018125277A (ru) | 2020-02-07 |
| JP6913274B2 (ja) | 2021-08-04 |
| US10626116B2 (en) | 2020-04-21 |
| CA3009256A1 (en) | 2017-07-13 |
| KR102688907B1 (ko) | 2024-07-29 |
| ES2875384T3 (es) | 2021-11-10 |
| AU2016384921C1 (en) | 2021-05-20 |
| AU2016384921A1 (en) | 2018-07-26 |
| EP3372607B1 (en) | 2021-04-28 |
| RU2728827C2 (ru) | 2020-07-31 |
| BR112018012106B1 (pt) | 2023-12-12 |
| CA3009256C (en) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018012106A2 (pt) | forma cristalina de inibidor de btk quinase e método de preparação da mesma | |
| ECSP19048759A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, y proceso para producir el modulador | |
| CL2018003504A1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CL2012001391A1 (es) | Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios. | |
| CR20160099A (es) | Formulación de inhibidores de la syk | |
| NI201800058A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. | |
| ECSP12011867A (es) | Derivados bencimidazol-imidazol | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| DOP2014000133A (es) | Triazolopiridinas sustituidas | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| DOP2015000245A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2015000170A (es) | Compuestos químicos | |
| CR10722A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| CY1116086T1 (el) | Ενυδρη υδροχλωρικη αγομελατινη και παρασκευη αυτης | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 | |
| EA201791671A1 (ru) | 4-замещенные соединения бензоксаборола и их применение | |
| BR112017018580A2 (pt) | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal | |
| BR112017007953A2 (pt) | forma cristalina de um bissulfato inibidor de jak quinase e método de preparação desse | |
| BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
| AR085909A1 (es) | Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras | |
| BR112017005454A2 (pt) | composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2016, OBSERVADAS AS CONDICOES LEGAIS |